Skin & hair

PTD-DBM

Wnt signaling in experimental hair models

Investigational; this profile does not establish an approved use.

What does it do?

Hair regeneration in mouse models

Lab research

Scope of investigation or explicitly identified community interest; not an established indication.1

Molecular information

1 16

Amino-acid sequence

25 residues · N → C16

Reference identity · not independently confirmed16

Length25 amino acids

Molecular weight · Da3,082.62 Da

Molecular formulaNot independently verified1 16

Identity reported by Pep-Pedia; exact-product sequence and modifications have not been independently confirmed.

Sequence and formulation must be confirmed for the exact material; similarly named products are not necessarily interchangeable.

Pharmacokinetics

Unverified reference estimateNot independently confirmed

Reference half-life2 hours15

Route / formulationSource page: Topical. Exact PK route not verified.

This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement.

Elapsed time 2 h

50%of reference level

Illustrative scenario using an unverified reference estimate.

About 3% remaining after 10 h

Five half-lives in this estimated model. This is not a prediction of when effects stop.

About this estimate

Population: Not established by the reference estimate

Source’s stated attribution: Lee SH et al. J Invest Dermatol 2017 (PMID 28595998) - depilation mouse model

Source’s reported peak time: 12 min. This has not been independently confirmed and is not used in the elimination curve.

100 × 2^{−time / half-life}. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.

What to expect

Study outcomes

Scope of evidence

Human scalp efficacy, tissue selectivity and long-term safety are unresolved.1

Reported timelines

Reference & community

Source expectations

No visible change weeks 1–4; possible emergence months 2–3 and density assessment 3–6. No validated human timeline.16

These are reported timelines, not a prediction of your response.

Doses & schedules

Scroll to compare all columns →

One row for each documented route and dose or dose range
Route	Dose	Frequency	Goal / evidence	Duration	References
TopicalDirect topical to wound or scalp area (PMID 26056233)	100 µM in PBS (approximately 308 mcg/mL)	Daily topical application for 11 days	Research Protocol (wound model, JEM 2015)Reference report	12-20 weeks	16
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Commercial-brand and route-superiority claims remain unverified; compatible labels do not establish safety. Source tabs Topical
TopicalScalp dropper or applied before 0.5-1.0 mm dermaroller	0.01-0.05% by mass (approximately 0.1-0.5 mg/mL reconstituted in bacteriostatic water)	Once or twice daily to thinning areas	Community approach (anecdotal, no peer-reviewed human data)Reference report	12-20 weeks	16
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Commercial-brand and route-superiority claims remain unverified; compatible labels do not establish safety. Source tabs Topical

Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.

Cycles & timing

Reference reports16

Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.

Topical

Use period: 12-20 weeks
Break: Assess response at 16 weeks; no published cycling protocol

Reported timing

Any consistent time; some combine with microneedling session

Injectable

Use period: Not established
Break: Not established

Reported timing

Unknown

Animal and cell protocols 2

Laboratory exposures cannot establish a human dose.

Scroll to compare all columns →

Animal and cell exposures
Route	Dose	Frequency	Goal / evidence	Duration	References
TopicalTopical to shaved or depilated dorsal scalp (PMID 36831222)	10 mM in PBS (approximately 30.8 mg/mL), 300 µL per application	Every other day, days 8-20 post-depilation	Research Protocol (depilated mouse, Cells 2023)Reference report	12-20 weeks	16
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Commercial-brand and route-superiority claims remain unverified; compatible labels do not establish safety. Source tabs Topical
TopicalIntra-wound injection in mouse (PMID 26056233); not a human scalp protocol	100 µM locally in wound margin	Applied per wound study design	Mouse wound model local injection (JEM 2015)Reference report	Not specified	16
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Commercial-brand and route-superiority claims remain unverified; compatible labels do not establish safety. Source tabs Injectable

Side effects & safety

Chronic pathway activation

Long-term effects of altering Wnt-related signaling in human scalp tissue remain unresolved.

Formulation uncertainty

Mouse formulations and a separate small molecule, KY19382, cannot establish safety of a research-vial scalp product.

Additional reported cautions

Reference reports16

Unknown safety

Repeated exposure, immunogenicity and systemic effects uncertain; Wnt overactivation raises theoretical proliferative concerns.

Stop symptoms

Persistent burning/redness, allergy, infection, systemic symptoms or worsening scalp condition.

Route

Mouse topical findings do not validate scalp injections.

Not a complete safety screen. Discuss health decisions with a qualified clinician.

Combinations & interactions

8 entries

Check cautions and reported pairings. A compatibility claim does not establish that a combination is safe.

Topical corticosteroids

Caution reported

Possible mechanistic antagonism.16

Reference report · Pep-Pedia label: Monitor Combination

Other Wnt agonists

Caution reported

Potential excessive signaling.16

Reference report · Pep-Pedia label: Use Caution

GHK-Cu

Unverified pairing

Unproven scalp stack.16

Reference report · Pep-Pedia label: Synergistic

Minoxidil

Unverified pairing

No direct combination trial.16

Reference report · Pep-Pedia label: Compatible

AHK-Cu

Unverified pairing

Untested pairing.16

Reference report · Pep-Pedia label: Compatible

Finasteride

Unverified pairing

Theoretical complement.16

Reference report · Pep-Pedia label: Compatible

Valproic acid

Unverified pairing

Mouse combination findings.16

Reference report · Pep-Pedia label: Synergistic

Other peptides and medicines

Not established

A controlled interaction assessment for this exact compound and formulation was not identified in the sources checked. Absence of interaction data is not evidence of compatibility.2

Research context

Reconstitution

No verified preparation instructions

A product-specific preparation or sterility protocol has not been verified.2

Dilution

A concentration calculation cannot establish a suitable diluent, compatibility, storage interval, or sterility. No universal bacteriostatic-water volume is assigned.2

Reference preparation details

Reported handling information, not a validated formulation or instruction to prepare an injectable product.

Topical

The source describes an experimental topical scalp solution.

Solvents mentioned: Bacteriostatic water
Reported parameters: Reported carrier: BAC water; light-protective packaging. · Reported storage: 2–8°C for 7 days.

Its 0.5–1 mL application and dermaroller suggestions are source claims, not established human delivery or safety instructions.

Injectable

Pep-Pedia states that no human injection protocol is established.

Solvents mentioned: Sterile PBS / Bacteriostatic water
Reported parameters: Dry material: reported −20°C. · Prepared solution: reported 2–8°C for 7 days.

The source describes gentle mixing and avoiding vigorous shaking.

Appearance & documentation

Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.

Reported appearanceWhite to off-white lyophilized powderReported appearanceCOA with HPLC purity 95% or higherReported appearanceCold-chain shipped, stored at -20°CReported appearanceReconstituted solution is clear with no precipitateReported variationProtect from light after reconstitutionReported variationResearch-grade only: no pharmaceutical-grade product existsReported concernCloudy, yellow-tinged, or precipitated solution

Available forms

No verified packaging examples included.

Packaging examples, not a market survey. Approved and research products are not interchangeable.

Storage after mixing

Reconstituted research vials

Pep-Pedia reports these handling limits after mixing. They are not validated stability or sterility limits for your vial.

Injectable

Unverified report16

2–8°C · 7 days

Topical

Unverified report16

2–8°C · 7 days

Storage notes

Topical

-20°C lyophilized. Reconstituted: 2-8°C, use within 7 days.

Injectable

Lyophilized: -20°C. Reconstituted: 2-8°C, use within 7 days

Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.

Evidence limits

View findings →

Human scalp efficacy, tissue selectivity and long-term safety are unresolved.1

1 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.

Evidence definitions →

Research findings

Preclinical

Source context

Commercial-brand and route-superiority claims remain unverified; compatible labels do not establish safety.

Compound identity & other names

PTD-DBM is a cell-penetrating construct designed to interfere with CXXC5–Dishevelled binding. Its hair-regeneration rationale comes from preclinical signaling and mouse experiments, not a verified human alopecia trial.

Other names: Protein transduction domain–Dishevelled binding motif

Investigational; this profile does not establish an approved use.

Cell-penetrating domain linked to a Dishevelled-binding motif; distinct from KY193821 16

Pep-Pedia identity record

25 amino acids · 3,082.62 Da

H-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Gly-Gly-Gly-Gly-Arg-Lys-Thr-Gly-His-Gln-Ile-Cys-Lys-Phe-Arg-Lys-Cys-OH

Reference description; checked chemical identity takes precedence when available.16

How it may work

Disrupts CXXC5–Dishevelled binding to relieve inhibition of Wnt/beta-catenin signaling.16

Hair growth in mouse models

PTD-DBM was tested in depilation and wound-induced hair-neogenesis models. Results for the separate small molecule KY19382 are not interchangeable.

Research areas and evidence gaps

Hair regeneration in mouse models. Scope of investigation or explicitly identified community interest; not an established indication.1

Human scalp efficacy, tissue selectivity and long-term safety are unresolved.
The evidence does not validate the identity, purity or handling of a separately sourced research product.

Additional uses listed by Pep-Pedia

Hair. Androgenetic alopecia, follicle cycling and wound-induced follicle formation.16

Skin. Wound repair and scalp-aging research; injection outcomes unestablished.16

Community reports Unvalidated

Pep-Pedia reports use in the research-peptide community. These reports are not clinical evidence.2

Pep-Pedia mixes mouse protocols and anecdotal scalp application. These must not be represented as human efficacy trials or verified home preparation instructions.

Search coverage and review status

Additional primary or regulatory sources were checked. No further 2025–2026 exact-compound clinical outcome study was identified in this targeted search; this is not evidence that none exists.

Checked: 2026-10-12
Search: PTD-DBM 2025 2026 study hair; PTD-DBM hair
Catalog: Pep-Pedia ↗ · 12 listed references retained

Targeted search, not a systematic or exhaustive review.
Retained bibliography entries marked Bibliography only have not been independently verified.
Distinct URLs may refer to the same publication; component and formulation boundaries remain important.

AI-prepared summaries. Independent medical editorial review is pending.

Community poll 1 topics · Pep-Pedia snapshot

Voluntary, unverified reports. These percentages do not measure effectiveness or safety.

Topic

Experience

Other: Nothing100%

Number of responses to this question: not disclosed.

Source & limitations

The source displays “1 response” for this profile. This is not a confirmed participant count or a denominator for individual questions.

Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
This is a dated snapshot, not a live survey or current recommendation.

References

Original sources and review status. Open a reference to read its summary.

16 sources

1CXXC5 Mediates DHT-Induced Androgenetic Alopecia via PGD2Preclinical · 2023 · pubmed.ncbi.nlm.nih.govAbstract checked

AI-PREPARED SUMMARY

Disrupting CXXC5–Dishevelled signaling was investigated in cells and mouse hair models.

Hair growth in mouse models

PTD-DBM was tested in depilation and wound-induced hair-neogenesis models. Results for the separate small molecule KY19382 are not interchangeable.

Additional research · Checked 2026-10-12

Original source

2Pep-Pedia: PTD-DBMCommunity · Accessed 2026 · pep-pedia.orgCommunity source checked

AI-PREPARED SUMMARY

Secondary community overview checked on 12 October 2026. Its practice tables and efficacy claims are not independently validated clinical guidance.

Original source

3Lee SH, Kim MY, Kim HY, Lee YM, Kim H, Nam KA, Roh MR, Min DS, Chung KY, Choi KY (2015). The Dishevelled-binding protein CXXC5 negatively regulates cutaneous wound healing. Journal of Experimental Medicine, 212(7), 1061-1080.Bibliography · 2015 · pmc.ncbi.nlm.nih.govPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: Mouse wounds closed faster and formed new follicles after topical exposure; five human biopsies assessed CXXC5 expression, not treatment efficacy.

Reported population / model
Mouse C57BL/6

Reported study details
PTD-DBM 100 µM topical in PBS · Daily x 11 days · Wound closure, beta-catenin, hair neogenesis

Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Listed study

4Lee SH, Seo SH, Lee DH, Pi LQ, Lee WS, Choi KY (2017). Targeting of CXXC5 by a Competing Peptide Stimulates Hair Regrowth and Wound-Induced Hair Neogenesis. Journal of Investigative Dermatology, 137(11), 2260-2269.Bibliography · 2017 · pubmed.ncbi.nlm.nih.govPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: Topical treatment restored mouse hair growth and altered human papilla-cell markers; combining valproate increased follicle formation in mice.

Reported population / model
Mouse C57BL/6N + human DP cells in vitro

Reported study details
PTD-DBM topical, PTD-DBM plus VPA · 12-20 days post-depilation · Anagen re-entry, beta-catenin, DP cell activation

Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Listed study

5Ryu YC, Park J, Kim YR, et al. (2023). CXXC5 Mediates DHT-Induced Androgenetic Alopecia via PGD2. Cells, 12(4), 555.Bibliography · 2023 · pmc.ncbi.nlm.nih.govPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: PTD-DBM reversed PGD2-related hair suppression in mice at high topical concentration; a safe effective human preparation was not established.

Reported population / model
Mouse depilated dorsal skin

Reported study details
PTD-DBM 10 mM topical, 300 µL per application · Every other day, days 8-20 · Hair shaft recovery, PGD2 pathway reversal

Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Listed study

6Ryu YC, Lee H, Kim J, et al. (2021). KY19382, a novel activator of Wnt/beta-catenin signalling, promotes hair regrowth and hair follicle neogenesis. British Journal of Pharmacology, 178(12), 2533-2546.Bibliography · 2021 · bpspubs.onlinelibrary.wiley.comPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: Successor molecule KY19382 outperformed the peptide in animal models and lengthened cultured human follicles; it is a different intervention.

Reported population / model
Mouse depilation model + human follicle ex vivo organ culture

Reported study details
KY19382 vs PTD-DBM comparator · 14-21 days · Hair regrowth, follicle elongation

Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Listed study

7Kim D, Garza LA (2017). The Negative Regulator CXXC5: Making WNT Look a Little Less Dishevelled. Journal of Investigative Dermatology, 137(11), 2248-2250.Bibliography · 2017 · pmc.ncbi.nlm.nih.govLinked reference · Not independently reviewed

REFERENCE NOTE